Aktis Oncology (AKTS) news
Recent news
Aktis Oncology Inc: Wedbush initiates coverage with outperform rating; target price $35
AInvest Wire · Aug 19, 2026Aktis Oncology Inc: Raymond James initiates coverage with strong buy rating; target price $40
Raymond James has initiated coverage of Aktis Oncology Inc (AKTS) with a "Strong Buy" rating and a target price of $40 per share, signaling confidence in the clinical-stage oncology company’s potential. Aktis Oncology, which focuses on developing targeted radiopharmaceuticals for large patient…
AInvest Wire · Jun 16, 2026ImportantAkoustis Technologies Shares Dive 32% on 20M-Share Offering
Akoustis Technologies Shares Dive 32% on 20M-Share Offering Akoustis Technologies, a radio frequency and wireless devices company, recently announced a proposed public share offering, which caused its stock to plummet by 32% [1]. The offering, which has not yet been priced or had its share amount…
AInvest Wire · Jan 25, 2024Akoustis Technologies drops 27% premarket after saying to offer and sell shares of its common stock via public offering
Akoustis Technologies drops 27% premarket after saying to offer and sell shares of its common stock via public offering Akoustis Technologies, a Nasdaq-listed integrated device manufacturer, experienced a significant drop in its premarket share price by 27% after announcing its plan to offer and…
AInvest Wire · Jan 25, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.